Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act

The Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act (S.339, HR842) proposes a structural change to Medicare coverage policy: starting January 1, 2028, CMS would cover FDA-approved multi-cancer early detection screening tests for beneficiaries under age 68 (increasing one year annually). The bill does not appropriate any specific funding — it authorizes coverage but actual payment amounts will be determined by CMS through a national coverage determination (NCD) process. This is a coverage authorization, not a direct appropriation. The money trail runs through Medicare Part B reimbursement: test developers (Exact Sciences, Guardant Health, GRAIL) would receive direct payment for each test administered to an eligible beneficiary. Reference laboratories (Labcorp, Quest Diagnostics) would capture processing and billing margin. Sequencing platform providers (Illumina) benefit indirectly through increased consumables demand as test volumes scale. The structural winners are clearly Exact Sciences and Labcorp ($LH). Exact Sciences' Cancerguard liquid biopsy is in late-stage development specifically targeting the multi-cancer and multi-cancer screening market; a guaranteed Medicare pathway converts development into revenue. Labcorp has existing CLIA infrastructure and partnerships with test developers to process tests at scale. Illumina ($ILMN) is a secondary beneficiary — sequencing volumes increase, but Illumina's revenue base is far more diversified. Castle Biosciences ($CSTL) is a longer-shot beneficiary requiring product pivot. Market data shows significant recent price weakness across the diagnostic sector: $ILMN down 4% in 7 days to $120.37 (near lower half of its 52-week range $73.86-$155.53), $LH down 2.94% to $257.14, $QGEN down 11.48% in 7 days to $33.61 (near 52-week low of $33.17), while $CSTL shows relative strength at +2.32% 7-day to $24.24. These declines appear driven by broader sector headwinds rather than bill-related factors, as the bill has been in committee since January 2025 with no recent catalyst. The legislative timeline is extended but viable: 68 cosponsors (bipartisan) with strong Senate sponsorship (Sen. Crapo, R-ID) and identical House companion HR842 which has been reported (amended) by Ways & Means — this means the House version has passed committee with a report. The 2028 start date reflects that no test is currently FDA-approved for multi-cancer detection; the timeframe allows for FDA approvals and CMS NCD development. Next milestones: House floor vote on HR842, then Senate Finance Committee markup of S.339.